HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.

Abstract
Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy. Since 1985, we have entered 30 IF patients into protocols using conditioning with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) followed by autologous stem cell transplantation (ASCT) with bone marrow (19 patients), peripheral blood stem cells (PBSCs; 8 patients), or both (3 patients). All except 2 patients had previously received chemotherapy regimens for HD that contained at least 7 drugs, and 9 had received prior radiotherapy (RT). After documentation of IF, the majority of patients received some cytoreductive therapy as specified by protocol (local RT in 9, two cycles of conventional chemotherapy in 2, both modalities in 2, or high-dose cyclophosphamide to enhance PBSC collection in 11) before CBV +/- P. Five treatment-related deaths occurred, all before day 150 posttransplant. Eleven patients have had progressive HD at a median of 6 months (range, 0.1 to 45 months) after ASCT. The actuarial progression-free survival (PFS) at a median follow-up of 3.6 years (range, 0.2 to 8.2 years) is 42% (95% confidence intervals, 21% to 61%). The statistical analysis identified only prior clinical bleomycin lung toxicity as an adverse risk factor for PFS, mainly because of the increased nonrelapse mortality seen in these patients. CBV +/- P and ASCT can produce durable remission in a substantial proportion of IF HD patients who otherwise have a poor survival, and we believed ASCT approaches represent the best therapy currently available for these patients. Additional measures are needed to reduce the primary problem of disease progression despite high-dose chemotherapy and stem cell transplantation.
AuthorsD E Reece, M J Barnett, J D Shepherd, D E Hogge, R J Klasa, S H Nantel, H J Sutherland, H G Klingemann, R N Fairey, N J Voss
JournalBlood (Blood) Vol. 86 Issue 2 Pg. 451-6 (Jul 15 1995) ISSN: 0006-4971 [Print] United States
PMID7541661 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Bleomycin
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Vinblastine
  • Etoposide
  • Dacarbazine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Cisplatin
  • Leucovorin
  • Carmustine
  • Prednisone
  • Methotrexate
Topics
  • Actuarial Analysis
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bleomycin (administration & dosage)
  • Bone Marrow Diseases (chemically induced, therapy)
  • Bone Marrow Transplantation
  • Carmustine (administration & dosage, adverse effects)
  • Cisplatin (administration & dosage, adverse effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Dacarbazine (administration & dosage)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage)
  • Etoposide (administration & dosage, adverse effects)
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease (drug therapy, mortality, radiotherapy, therapy)
  • Humans
  • Leucovorin (administration & dosage)
  • Male
  • Mechlorethamine (administration & dosage)
  • Methotrexate (administration & dosage)
  • Prednisolone (administration & dosage)
  • Prednisone (administration & dosage)
  • Procarbazine (administration & dosage)
  • Remission Induction
  • Salvage Therapy
  • Survival Analysis
  • Treatment Outcome
  • Vinblastine (administration & dosage)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: